Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Beate Klimm"'
Autor:
Elisabeth Schorb, Benjamin Kasenda, Johannes Atta, Stephan Kaun, Anke Morgner, Georg Hess, Thomas Elter, Nikolas von Bubnoff, Martin Dreyling, Mark Ringhoffer, Stefan W. Krause, Günter Derigs, Beate Klimm, D. Niemann, Kristina Fritsch, Jürgen Finke, Gerald Illerhaus
Publikováno v:
Haematologica, Vol 98, Iss 5 (2013)
High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis
Externí odkaz:
https://doaj.org/article/7c9b5dcb86444f11bffc7618729dc3c3
Autor:
Josée M. Zijlstra, Stefan Balabanov, Carsten Kobe, Hans Theodor Eich, Richard Greil, Julia Meissner, Alden A. Moccia, Teresa V Halbsguth, Volker Diehl, Paul J Bröckelmann, Judith Dierlamm, Ulrich Keller, Bastian von Tresckow, Christian Baues, Michael Fuchs, Annette Plütschow, Helmut Ostermann, Simone Marnitz, Martin Wilhelm, Sonja Martin, Beate Klimm, Julia Thiemer, Peter Borchmann, Thomas Pabst, Johannes Mohm, Michael Hallek, Andreas Rosenwald, Markus Dietlein, Andreas Hüttmann, Martin Vogelhuber, Max S. Topp, Martin Sökler, Andreas Engert, Andrea Kerkhoff, Miriam Ahlborn, Georg Kuhnert
Publikováno v:
The Lancet Oncology, 22(2), 223-234. Lancet Publishing Group
Borchmann, P, Plütschow, A, Kobe, C, Greil, R, Meissner, J, Topp, M S, Ostermann, H, Dierlamm, J, Mohm, J, Thiemer, J, Sökler, M, Kerkhoff, A, Ahlborn, M, Halbsguth, T V, Martin, S, Keller, U, Balabanov, S, Pabst, T, Vogelhuber, M, Hüttmann, A, Wilhelm, M, Zijlstra, J M, Moccia, A, Kuhnert, G, Bröckelmann, P J, von Tresckow, B, Fuchs, M, Klimm, B, Rosenwald, A, Eich, H, Baues, C, Marnitz, S, Hallek, M, Diehl, V, Dietlein, M & Engert, A 2021, ' PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 2, pp. 223-234 . https://doi.org/10.1016/S1470-2045(20)30601-X
Strahlentherapie Und Onkologie
Borchmann, P, Plütschow, A, Kobe, C, Greil, R, Meissner, J, Topp, M S, Ostermann, H, Dierlamm, J, Mohm, J, Thiemer, J, Sökler, M, Kerkhoff, A, Ahlborn, M, Halbsguth, T V, Martin, S, Keller, U, Balabanov, S, Pabst, T, Vogelhuber, M, Hüttmann, A, Wilhelm, M, Zijlstra, J M, Moccia, A, Kuhnert, G, Bröckelmann, P J, von Tresckow, B, Fuchs, M, Klimm, B, Rosenwald, A, Eich, H, Baues, C, Marnitz, S, Hallek, M, Diehl, V, Dietlein, M & Engert, A 2021, ' PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 2, pp. 223-234 . https://doi.org/10.1016/S1470-2045(20)30601-X
Strahlentherapie Und Onkologie
Background: Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. However, the use of radiotherapy can have long-term sequelae, which is
Autor:
Jean M. Connors, Robert Pearcey, Michael Crump, Andreas Lohri, Bingshu E. Chen, Michael Fuchs, Peter Borchmann, Sandra J. Horning, Annette E. Hay, Jana Markova, Jane N. Winter, Volker Diehl, Lois E. Shepherd, Ralph M. Meyer, Andreas Engert, Mary Gospodarowicz, Helen Goergen, Hans-Theodor Eich, Bernd Dörken, Beate Klimm
Publikováno v:
Annals of Oncology. 24:3065-3069
Background Treatment options for patients with nonbulky stage IA-IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT), and chemother
Autor:
Hans-Theodor Eich, Volker Diehl, Michael Fuchs, Julia Meissner, A. Glunz, Andreas Engert, Peter Borchmann, Helen Goergen, B. von Tresckow, B. Böll, Beate Klimm
Publikováno v:
Annals of Oncology. 24:3070-3076
Background In early-stage Hodgkin's lymphoma (HL), treatment according to the early favorable or unfavorable subgroup is guided by staging definitions, which differ between various study groups worldwide. We analyzed risk factors used in different in
Autor:
Johannes Atta, Thomas Elter, Stephan Kaun, Dirk Niemann, G Derigs, Mark Ringhoffer, Anke Morgner, Elisabeth Schorb, Gerald Illerhaus, Nikolas von Bubnoff, Beate Klimm, Kristina Fritsch, Jürgen Finke, Stefan W. Krause, Martin Dreyling, Georg Hess, Benjamin Kasenda
Publikováno v:
Haematologica. 98:765-770
High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis
Autor:
Martin Wilhelm, A. Heyden-Honerkamp, O. Koch, Peter Borchmann, Rolf-Peter Müller, Hans-Theodor Eich, Volker Diehl, Andreas Lohri, Andreas Engert, G. Trenn, Jürgen Finke, S. Sasse, Helen Görgen, Michael Fuchs, Beate Klimm
Publikováno v:
Annals of Oncology. 23:2953-2959
Background To evaluate long-term toxicity and efficacy of a combined modality strategy including extended-field radiotherapy (EF-RT) or involved-field radiotherapy (IF-RT), the German Hodgkin Study Group carried out a follow-up analysis in patients w
Autor:
Max S. Topp, Hans Theodor Eich, Volker Diehl, Beate Klimm, Zdenek Kral, Martin Soekler, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Jana Markova, Annette Plütschow, Michael Fuchs, Josée M. Zijlstra, Richard Greil, Harald Stein, Julia Meissner, Andreas Lohri, Rolf P. Mueller
Publikováno v:
Journal of Clinical Oncology, 30(9), 907-913. American Society of Clinical Oncology
von Tresckow, B, Pluetschow, A, Fuchs, M, Klimm, B, Markova, J, Lohri, A, Kral, Z, Greil, R, Topp, M S, Meissner, J, Zijlstra-Baalbergen, J M, Soekler, M, Stein, H, Eich, H T, Mueller, R P, Diehl, V, Borchmann, P & Engert, A 2012, ' Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial ', Journal of Clinical Oncology, vol. 30, no. 9, pp. 907-913 . https://doi.org/10.1200/JCO.2011.38.5807
von Tresckow, B, Pluetschow, A, Fuchs, M, Klimm, B, Markova, J, Lohri, A, Kral, Z, Greil, R, Topp, M S, Meissner, J, Zijlstra-Baalbergen, J M, Soekler, M, Stein, H, Eich, H T, Mueller, R P, Diehl, V, Borchmann, P & Engert, A 2012, ' Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial ', Journal of Clinical Oncology, vol. 30, no. 9, pp. 907-913 . https://doi.org/10.1200/JCO.2011.38.5807
Purpose In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor con
Autor:
Andreas Engert, Beate Klimm
Publikováno v:
Nature Clinical Practice Oncology. 5:316-323
With improved treatment strategies and prognosis for patients with Hodgkin lymphoma (HL), interest has increasingly focused on high-risk groups. These groups include a small proportion of patients who experience relapse or who have primary refractory
Autor:
G. Trenn, Hans-Theodor Eich, Konrad Müller-Hermelink, Eckhart Dühmke, P. Worst, Beate Klimm, Volker Diehl, Andreas Lohri, F. Boissevain, Heinz Haverkamp, Andreas Engert, Peter Koch, Rolf-Peter Müller, Beate Pfistner
Publikováno v:
Annals of Oncology. 18:357-363
Background: The optimal treatment of elderly patients with Hodgkin’s lymphoma (HL) is still a matter of debate. Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field sizes, that is ex
Autor:
Ulrich Jaehde, Matthias Schwab, Andreas Josting, Alexander Jetter, Stefan Wilde, Dagmar Busse, Beate Klimm, Georg Hempel, Dirk Kasel, S. Rietbrock, Andreas Engert, Uwe Fuhr, S. Reif, U. Merkel, Volker Diehl
Publikováno v:
Clinical Pharmacokinetics. 46:319-333
The BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) chemotherapy regimen for the treatment of advanced Hodgkin’s lymphoma has a superior outcome, but its toxicity (mainly haematotoxicity) is p